Acamprosate calcium - CAS 77337-73-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acamprosate calcium
Catalog Number:
77337-73-6
Synonyms:
Calcium 3-acetamidopropane-1-sulfonate;Calcium 3-(acetylamino)propanesulphonate;3-(Acetylamino)-1-propanesulfonic Acid Calcium Salt;Calcium Acetylhomotaurine ;Alcomed;Sobriol;Aotal calcium;Calcium N-acetylhomotaurinate
CAS Number:
77337-73-6
Description:
Acamprosate calcium is a gamma-aminobutyric acid(GABA)agonist and modulator of glutamatergic systems. It has been used in alcohol dependence treatments and may be an effective augmentation therapy in patients with treatment-resistant anxiety. It has low bioavailability, but also has an excellent tolerability and safety profile. It is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so it can be administered to patients with hepatitis or liver disease and to patients who continue drinking alcohol. It was approved for use in the therapy of alcohol dependence and abuse in the United States in 2004.
Molecular Weight:
400.48
Molecular Formula:
C10H20CaN2O8S2
Quantity:
Grams to Kilograms
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
InChI:
InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2
InChIKey:
BUVGWDNTAWHSKI-UHFFFAOYSA-L
Targets:
GABA Receptor
Current Developer:
It has been approved the listing.
Chemical Structure
CAS 77337-73-6 Acamprosate calcium

Related GABA Receptor Products


CI966
(CAS: 110283-79-9)

CI966 is a highly potent and selective blocker of the GABA transporter 1 (GAT-1) with IC50 value of 0.26 µM acting as a central nervous system depressant. It ha...

CAS 64603-91-4 Gaboxadol

Gaboxadol
(CAS: 64603-91-4)

Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-...

CAS 64-65-3 Bemegride

Bemegride
(CAS: 64-65-3)

Bemegride is a central nervous system stimulant and antidote for barbiturate poisoning.

CAS 33125-97-2 Etomidate

Etomidate
(CAS: 33125-97-2)

Etomidate is a GABAA receptor agonist, used as a short-acting anaesthetic agent or sedative.

Remimazolam benzenesulfonat
(CAS: 1001415-66-2)

Remimazolam, a novel Benzodiazepine derivatives, has potential use for anxiolytic, sedative and hypnotic. For the reason that remimazolam's beding discontinued ...

CP-457920
(CAS: 220860-50-4)

CP-457920, also called as NGD 971, is a selective α5 GABAA receptor inverse agonist (Ki of ~ 1 ng/mL). CP-457920 was progressed into clinical studies for the tr...

CAS 77191-36-7 Nefiracetam

Nefiracetam
(CAS: 77191-36-7)

Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal system enhancer for Ro 5-4864-induced convulsions.

CAS 21715-46-8 Etifoxine

Etifoxine
(CAS: 21715-46-8)

Etifoxine, also called as HOE 36801 or Stresam, is a positive allosteric modulator of GABAreceptors that produces anxiolytic effects by preferentially modulatin...

CAS 62666-20-0 Progabide

Progabide
(CAS: 62666-20-0)

Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...

CAS 951650-22-9 NS 11394

NS 11394
(CAS: 951650-22-9)

NS 11394 is a drug with selectivity for the α3 and α5 subtypes. It acts as a subtype-selective positive allosteric modulator at GABAA receptors. It is used as a...

TPA023
(CAS: 252977-51-8)

TPA023, also called as MK-0777, is a subtype-selective, mixed agonist-antagonist at GABAA receptor with anxiolytic and anticonvulsant effects.

GS 39783
(CAS: 39069-52-8)

GS 39783 is an allosteric positive modulator of GABAB receptors, decreases cocaine self-administration, blocks the rewarding properties of nicotine and produces...

CAS 847353-30-4 Arbaclofen placarbil

Arbaclofen placarbil
(CAS: 847353-30-4)

Arbaclofen placarbil is a prodrug of R-baclofen. It is a GABA B receptor agonist. Arbaclofen was being developed as a potential treatment for patients with GERD...

CAS 57717-80-3 CGP7930

CGP7930
(CAS: 57717-80-3)

CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...

CAS 783331-24-8 MRK 016

MRK 016
(CAS: 783331-24-8)

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid...

CAS 56287-74-2 Afloqualone

Afloqualone
(CAS: 56287-74-2)

Afloqualone is a agonist of GABA receptor has sedative and muscle-relaxant effects.

CAS 207306-50-1 TB 21007

TB 21007
(CAS: 207306-50-1)

TB 21007, as a nootropic drug, is a GABAA receptor inverse agonist selective for the α5-subtype (Ki values are 1.6, 16, 20 and 20 nM for α5, α2, α1 and α3 subty...

CAS 130477-52-0 L-655,708

L-655,708
(CAS: 130477-52-0)

L-655,708, an inverse agonist of α5 subunit involved in GABAA receptor, has been found to exhibit cognitive performance improvement in biological studies.

CAS 840486-93-3 adipiplon

adipiplon
(CAS: 840486-93-3)

Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able ...

CAS 1134-47-0 Baclofen

Baclofen
(CAS: 1134-47-0)

Baclofen, an agonist of GABAB receptor, could be effective as a skeletal muscle relaxant and has been also found to have antispastic effect.

Reference Reading


1.Modulation of learning and memory by natural polyamines.
Guerra GP1, Rubin MA2, Mello CF3. Pharmacol Res. 2016 Mar 22. pii: S1043-6618(16)30189-X. doi: 10.1016/j.phrs.2016.03.023. [Epub ahead of print]
Spermine and spermidine are natural polyamines that are produced mainly via decarboxylation of l-ornithine and the sequential transfer of aminopropyl groups from S-adenosylmethionine to putrescine by spermidine synthase and spermine synthase. Spermine and spermidine interact with intracellular and extracellular acidic residues of different nature, including nucleic acids, phospholipids, acidic proteins, carboxyl- and sulfate-containing polysaccharides. Therefore, multiple actions have been suggested for these polycations, including modulation of the activity of ionic channels, protein synthesis, protein kinases, and cell proliferation/death, within others. In this review we summarize these neurochemical/neurophysiological/morphological findings, particularly those that have been implicated in the improving and deleterious effects of spermine and spermidine on learning and memory of naïve animals in shock-motivated and nonshock-motivated tasks, from a historical perspective.
2.Potential Medications for the Treatment of Alcohol Use Disorder: An Evaluation of Clinical Efficacy and Safety.
Litten RZ1, Wilford BB2, Falk DE1, Ryan ML1, Fertig JB1. Subst Abus. 2016 Feb 29:0. [Epub ahead of print]
Alcohol use disorder (AUD), as currently defined in the Diagnostic and Statistical Manual, Fifth Edition (DSM-5), is a heterogeneous disorder stemming from a complex interaction of neurobiological, genetic, and environmental factors. As a result of this heterogeneity, there is no one treatment for AUD that will work for everyone. During the past two decades, efforts have been made to develop a menu of medications to give patients and clinicians more choices when seeking a therapy that is both effective and which has limited side effects. To date, three medications have been approved by the U.S. Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a number of alternative medications are now being evaluated for treatment of AUD in human studies. Although not approved by the FDA for the treatment of AUD, in some cases, these alternative medications are being used off-label by clinicians for this purpose.
3.Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
Sinclair JM1,2, Chambers SE3, Shiles CJ3,4, Baldwin DS3,5. Drug Saf. 2016 Mar 29. [Epub ahead of print]
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions.
4.Alcoholic liver disease and hepatitis C virus infection.
Novo-Veleiro I1, Alvela-Suárez L1, Chamorro AJ1, González-Sarmiento R1, Laso FJ1, Marcos M1. World J Gastroenterol. 2016 Jan 28;22(4):1411-20. doi: 10.3748/wjg.v22.i4.1411.
Alcohol consumption and hepatitis C virus (HCV) infection have a synergic hepatotoxic effect, and the coexistence of these factors increases the risk of advanced liver disease. The main mechanisms of this effect are increased viral replication and altered immune response, although genetic predisposition may also play an important role. Traditionally, HCV prevalence has been considered to be higher (up to 50%) in alcoholic patients than in the general population. However, the presence of advanced alcoholic liver disease (ALD) or intravenous drug use (IDU) may have confounded the results of previous studies, and the real prevalence of HCV infection in alcoholic patients without ALD or prior IDU has been shown to be lower. Due to the toxic combined effect of HCV and alcohol, patients with HCV infection should be screened for excessive ethanol intake. Patients starting treatment for HCV infection should be specifically advised to stop or reduce alcohol consumption because of its potential impact on treatment efficacy and adherence and may benefit from additional support during antiviral therapy.